Medical Radiology and Radiation Safety. 2014. Vol. 59. No. 5. P. 37-54


I.P. Aslanidis1, D.M. Pursanova1, O.V. Mukhortova1, T.A. Katunina1, O.B. Karyakin2, V.A. Biryukov2

The Role of 11C-/18F-Choline PET/CT in the Detection of Recurrent Prostate Cancer in Patients with Biochemical Recurrence

1. A.N. Bakoulev Center for Cardiovascular Surgery of RAMS, Russia, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. ; 2. Medical Radiation Research Center, Obninsk, Russia


  1. Introduction
  2. Diagnostic Evaluation of Prostate Cancer Relapse

      2.1. PSA Serum Level and PSA Kinetics in Prostate Cancer Patients With Biochemical Relapse

      2.2. Transrectal Ultrasonography

      2.3. Bone Scintigraphy

      2.4. Computer Tomography

      2.5. Magnetic-resonance Tomography

  1. PET/CT with non-choline radiopharmaceuticals in Prostate Cancer Patients

      3.1. 18F-FDG

      3.2. 11C-acetate

      3.3. 11C-methionine

      3.4. 18F-fluorodihydrotestosterone (18F-FDHT)

      3.5. 18F-fluorothymidine (18FLT)

      3.6. 18F-fluoromethylarabinofuranosyluracil FMAU)

      3.7. 68Gallium-labelled Prostate-Spesific Membrane Antigen (68Ga-PSMA)

  1. 11C-/18F-Choline PET/CT

      4.1. 11C-/18F-Choline PET/CT in Primary Diagnosis of Prostate Cancer

      4.2. 11C-/18F-Choline PET/CT in Staging of Prostate Cancer

      4.3. 11C-/18F-Choline PET/CT in Early Relapse of Prostate Cancer

      4.4. 11C-/18F-Choline PET/CT for Detection of Bone Metastases in Prostate Cancer Patients

  1. Conclusion.

Key words: prostate cancer, PET/CT, C-Choline, 18F-Choline, PSA, PSA kinetics